Table 1.
Overview of the inhibitors used for the experiments in Figs. 6 and 7, their main molecular targets, the disease site for which clinical trials have been performed and the clinical trial phase. The last 2 columns show the pathway activation status at 2 months after a single-dose (SD) irradiation of 10 Gy and the efficacy of the inhibitor in 10 Gy SD long-term cultures.
| Inhibitor | Target(s) | Tumor type | Clinical trial phase | Pathway activation | Drug efficacy |
|---|---|---|---|---|---|
| Capivasertib (AZD5363) | AKT | Breast, prostate | Phase 3 | + | + |
| Ipatasertib (GDC-0068) | AKT | Breast, prostate | Phase 3 | + | + |
| BMS-754807 | IGF-1R/InsR | Breast, metastatic solid tumors | Phase 2 | + | + |
| Cabozantinib (XL184) | VEGFR2 | Liver, thyroid, prostate, lung | Phase 4 | + | + |
| Foretinib (GSK1363089) | MET/VEGFR2 | Breast, lung, renal, HNSCC | Phase 2 | + | + |
| Trametinib (GSK1120212) | MEK1/2 | Melanoma, solid tumors | Phase 4 | + | + |
| Ralimetinib (LY2228820) | p38 MAPK | Breast, Glioblastoma | Phase 2 | + | + |
| Sorafenib (BAY 43-9006) | multikinase | Liver, renal | Phase 4 | + | + |
| Dasatinib (BMS-354825) | Abl, Src, c-Kit | Leukemia, Lymphoma, prostate, lung | Phase 4 | + | + |
| Lapatinib (GSK572016) | EGFR, ErbB2 | Breast, gastrointestinal, HNSCC | Phase 4 | + | unchanged |
| Dinaciclib (PS-095760) | CDK | Leukemia, melanoma, lung | Phase 3 | + | + |
| Panobinostat (LBH589) | HDAC | Leukemia, multiple myeloma, lymphoma | Phase 3 | − | − |
| Vorinostat (SAHA) | HDAC | Lymphoma, multiple myeloma, lung | Phase 3 | − | − |